GlassScriptPhysician profile
Curtis R Powell
NPI 1912978511
$16,002.49
in general payments reported to CMS, 2019-2025
50 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what 79% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,981 · 2020: $1,721 · 2021: $4,650 · 2022: $2,466 · 2023: $1,793 · 2024: $1,499 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,736 · Education: $235 · Honoraria: $150 · Gift: $64.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,736.45 |
| Education | $235.04 |
| Honoraria | $150.00 |
| Gift | $64.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $5,302.82 | 2020-2024 | Axonics |
| Medtronic USA, INC. | $1,884.74 | 2019-2020 | |
| Astellas Pharma US INC | $877.80 | 2019-2024 | |
| Medtronic, INC. | $824.71 | 2022-2025 | Interstim |
| Boston Scientific Corporation | $643.64 | 2019-2025 | Axonics, Advantage System, Lumenis Pulse 120h |
| Coloplast Corp | $642.35 | 2019-2024 | |
| Caldera Medical, INC | $629.93 | 2021-2023 | Desara |
| Janssen Biotech, INC. | $612.75 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $572.20 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $428.67 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $327.55 | 2023-2025 | |
| Calyxo, INC. | $273.42 | 2025 | Cvac Aspiration System |
| Merck Sharp & Dohme LLC | $265.92 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Biotissue Holdings INC. | $265.13 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $254.39 | 2021-2025 |
Show all 48 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,127.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.